Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.71 |
| ▸ | HTR2C | P28335 | 13/20 | 0.71 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.52 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.52 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.52 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5646747 | 0.90 | MCHR1 (0.73) | MCHR1HTR2CKCNQ3KCNQ2KCNE1 | |
| SCHEMBL5651597 | 0.83 | MCHR1 (1.00) | MCHR1HTR2C | |
| SCHEMBL5646061 | 0.83 | MCHR1 (0.98) | MCHR1HTR2C | |
| SCHEMBL6490307 | 0.83 | MCHR1 (0.98) | MCHR1HTR2C | |
| SCHEMBL5645579 | 0.82 | MCHR1 (0.73) | MCHR1HTR2CPTPN1KCNQ3KCNQ2 | |
| SCHEMBL20762665 | 0.81 | MCHR1 (0.60) | MCHR1HTR2CPTPN1KCNQ3KCNQ2 | |
| SCHEMBL5646506 | 0.79 | MCHR1 (0.80) | MCHR1HTR2C | |
| SCHEMBL5647773 | 0.78 | MCHR1 (0.79) | MCHR1HTR2C | |
| SCHEMBL5647011 | 0.78 | MCHR1 (0.77) | MCHR1HTR2C | |
| SCHEMBL5645754 | 0.78 | MCHR1 (0.68) | MCHR1HTR2CMAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050209213-A1 | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1447402-A1 | QUINOLINE COMPOUND | Takeda Chemical Industries, Ltd. (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209213-A1 | Quinoline compound | MC1R, MC2R, TYR | MCHR1 4/4885HTR2C 36/4885PTPN1 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.